Intellia Therapeutics
NTLA
290 hedge funds and large institutions have $2.02B invested in Intellia Therapeutics in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 114 increasing their positions, 88 reducing their positions, and 37 closing their positions.
30% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 37
30% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 88
2% more funds holding
Funds holding: 284 → 290 (+6)
1.61% less ownership
Funds ownership: 95.02% → 93.41% (-1.6%)
20% less capital invested
Capital invested by funds: $2.51B → $2.02B (-$497M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
32% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $27.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$14.4M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14M |
| 3 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$13.4M |
| 4 |
BlackRock
New York
|
+$11.6M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$9.23M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.05M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$8.9M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$8.17M |
NTLA Hedge Fund Activity: Q2 2024 in Review
290 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2024, worth a combined $2.02B — down 20% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NTLA positions and 37 closed out — a net gain of 11 holders — while 114 added to existing stakes and 88 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $14.4M. The largest seller was Wellington Management Group, cutting an estimated $80.5M.
- 290 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2024, up from 284 in Q1 2024.
- Funds reported $2.02B of Intellia Therapeutics stock for Q2 2024, down 20% quarter-over-quarter.
- 48 funds opened new Intellia Therapeutics positions in Q2 2024 and 37 closed out, a net change of +11 holders.
- The largest Intellia Therapeutics buyer in Q2 2024 was ARK Investment Management, an estimated $14.4M added.
- The largest Intellia Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $80.5M sold.
Based on aggregated 13F filings for Q2 2024.